In a report released today, Brian Tanquilut from Jefferies reiterated a Hold rating on Mednax Inc (NYSE: MD), with a price target of $48. The company’s shares closed yesterday at $44.06, close to its 52-week low of $40.56.
According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of 5.5% and a 54.7% success rate. Tanquilut covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Walgreens Boots Alliance, and Quest Diagnostics Inc.
Currently, the analyst consensus on Mednax Inc is a Hold with an average price target of $49.80, representing a 13.0% upside. In a report issued on July 12, Leerink Partners also initiated coverage with a Hold rating on the stock with a $50 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $63.04 and a one-year low of $40.56. Currently, Mednax Inc has an average volume of 824.5K.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MEDNAX, Inc. provides physician services including newborn, anesthesia, maternal-fetal, tele radiology, pediatric cardiology and other pediatric subspecialty care. The company’s solution include anesthesiology & pain management, prenatal, neonatal, pediatric, radiology, tele radiology, revenue cycle management and perioperative improvement consulting.
